Focal malformations of cortical development: New vistas for molecular pathogenesis

Neuroscience

Volumn 252, Issue , 2013, Pages 262-276

  Lim, K C ^a   Crino, P B ^b  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

^b TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Autism; Epilepsy; Malformations of cortical development; MTOR; Rapamycin

Indexed keywords

CD34 ANTIGEN; EPIDERMAL GROWTH FACTOR RECEPTOR; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 2; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PHOSPHOINOSITIDE DEPENDENT PROTEIN KINASE 1; PROTEIN KINASE B; RAPAMYCIN; S6 KINASE; SOMATOMEDIN C; TUBERIN;

AKT3 GENE; ALEXANDER DISEASE; AUTOSOMAL DOMINANT DISORDER; AUTOSOMAL RECESSIVE DISORDER; CANCER SURGERY; CLINICAL FEATURE; COMPLEX FORMATION; CORTICAL DYSPLASIA; DISEASE ASSOCIATION; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; EPILEPSY; EPILEPTOGENESIS; FOCAL MALFORMATION OF CORTICAL DEVELOPMENT; GENE; GENE DELETION; GLIOMA; HISTOPATHOLOGY; HISTORY OF MEDICINE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; INFANTILE SPASM; LOSS OF FUNCTION MUTATION; MOLECULAR PATHOLOGY; NEUROPATHOLOGY; NONHUMAN; PAPILLOMAVIRUS INFECTION; PI3K GENE; POINT MUTATION; POLYHYDRAMNIOS MEGALENCEPHALY SYMPTOMATIC EPILEPSY SYNDROME; PRIORITY JOURNAL; REVIEW; SEIZURE; SIGNAL TRANSDUCTION; STRADA GENE; SUBEPENDYMAL GIANT CELL ASTROCYTOMA; SYNDROME; TERATOGENICITY; TSC1 GENE; TSC2 GENE; TUBEROUS SCLEROSIS;

ATGC; ATYPICAL GANGLION CELL; AUTISM; BALLOON CELL; BC; DN; DYSMORPHIC NEURON; EPILEPSY; FCD; FMCD; FOCAL CORTICAL DYSPLASIAS; FOCAL MALFORMATIONS OF CORTICAL DEVELOPMENT; GANGLIOGLIOMA; GC; GFAP; GG; GIANT CELL; GLIAL FIBRILLARY ACIDIC PROTEIN; HEMIMEGALENCEPHALY; HME; HPV16; HUMAN PAPILLOMAVIRUS TYPE 16; MAGNETIC RESONANCE IMAGING; MALFORMATIONS OF CORTICAL DEVELOPMENT; MAMMALIAN TARGET OF RAPAMYCIN; MCAP; MCD; ME/ID; MEGALENCEPHALY AND INTELLECTUAL DISABILITY; MEGALENCEPHALY-CAPILLARY MALFORMATION; MEGALENCEPHALY-POLYMICROGYRIA-POLYDACTYLY-HYDROCEPHALUS; MPPH; MRI; MTOR; MTOR COMPLEX 1; MTOR COMPLEX 2; MTORC1; MTORC2; P70S6K; P70S6KINASE; PDK1; PHOSPHATASE AND TENSIN HOMOLOG DELETED IN CHROMOSOME TEN; PHOSPHATIDYLINOSITOL 3-KINASE; PHOSPHOINOSITIDE-DEPENDENT KINASE-1; PI3K; PMSE; POLYHYDRAMNIOS-MEGALENCEPHALY-SYMPTOMATIC-EPILEPSY SYNDROME; PTEN; RAPAMYCIN; RAS HOMOLOG ENRICHED IN BRAIN; RHEB; TBC1 DOMAIN FAMILY MEMBER 7; TBC1D7; TSC; TUBEROUS SCLEROSIS COMPLEX; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGF;

ANIMALS; HUMANS; MALFORMATIONS OF CORTICAL DEVELOPMENT; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES;

EID: 84884171372     PISSN: 03064522     EISSN: 18737544     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2013.07.037     Document Type: Review

References (115)

1. Anderl S., Freeland M., Kwiatkowski D.J., Goto J. Therapeutic value of prenatal rapamycin treatment in a mouse brain model of tuberous sclerosis complex. Hum Mol Genet 2011, 20(23):4597-4604.
2. Arbeit J.M., Munger K., Howley P.M., Hanahan D. Neuroepithelial carcinomas in mice transgenic with human papillomavirus type 16 E6/E7 ORFs. Am J Pathol 1993, 142:1187-1197.
3. Aronica E., Becker A.J., Spreafico R. Malformations of cortical development. Brain Pathol 2012, 22:380-401.
4. Aronica E., Boer K., Baybis M., Yu J., Crino P. Co-expression of cyclin D1 and phosphorylated ribosomal S6 proteins in hemimegalencephaly. Acta Neuropathol 2007, 114:287-293.
5. Barkovich A.J., Guerrini R., Kuzniecky R.I., Jackson G.D., Dobyns W.B. A developmental and genetic classification for malformations of cortical development: update 2012. Brain 2012, 135:1348-1369.
6. Barkovich A.J., Kuzniecky R.I., Dobyns W.B., Jackson G.D., Becker L.E., Evrard P. A classification scheme for malformations of cortical development. Neuropediatrics 1996, 1996:59-63.
7. Baybis M., Yu J., Lee A., Golden J.A., Weiner H., McKhann G., Aronica E., Crino P.B. MTOR cascade activation distinguishes tubers from focal cortical dysplasia. Ann Neurol 2004, 56:478-487.
8. Becker L.E. Central neuronal tumors in childhood: relationship to dysplasia. J Neurooncol 1995, 24:13-19.
9. Becker A.J., Urbach H., Scheffler B., Baden T., Normann S., Lahl R., Pannek H.W., Tuxhorn I., Elger C.E., Schramm J., Wiestler O.D., Blumcke I. Focal cortical dysplasia of Taylor's balloon cell type: mutational analysis of the TSC1 gene indicates a pathogenic relationship to tuberous sclerosis. Ann Neurol 2002, 52:29-37.
10. Ben-Sahra I., Howell J.J., Asara J.M., Manning B.D. Stimulation of de novo pyrimidine synthesis by growth signaling through mTOR and S6K1. Science 2013, 339(6125):1323-1328.
11. Blumcke I., Giencke K., Wardelmann E., Beyenburg S., Kral T., Sarioglu N., Pietsch T., Wolf H.K., Schramm J., Elger C.E., Wiestler O.D. The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol 1999, 97:481-490.
12. Blumcke I., Muhlebner A. Neuropathological work-up of focal cortical dysplasias using the new ILAE consensus classification system - practical guideline article invited by the Euro-CNS Research Committee. Clin Neuropathol 2011, 30:164-177.
13. Blumcke I., Thom M., Aronica E., Armstrong D.D., Vinters H.V., Palmini A., Jacques T.S., Avanzini G., Barkovich A.J., Battaglia G., Becker A., Cepeda C., Cendes F., Colombo N., Crino P., Cross J.H., Delalande O., Dubeau F., Duncan J., Guerrini R., Kahane P., Mathern G., Najm I., Ozkara C., Raybaud C., Represa A., Roper S.N., Salamon N., Schulze-Bonhage A., Tassi L., Vezzani A., Spreafico R. The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 2011, 52:158-174.
14. Blumcke I., Wiestler O.D. Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J Neuropathol Exp Neurol 2002, 61:575-584.
15. Boer K., Troost D., Jansen F., Nellist M., van den Ouweland A.M., Geurts J.J., Spliet W.G., Crino P., Aronica E. Clinicopathological and immunohistochemical findings in an autopsy case of tuberous sclerosis complex. Neuropathology 2008, 28(6):577-590. [Epub 2008 Apr 11]. 10.1111/j.1440-1789.2008.00920.x.
16. Boer K., Troost D., Spliet W.G., van Rijen P.C., Gorter J.A., Aronica E. Cellular distribution of vascular endothelial growth factor A (VEGFA) and B (VEGFB) and VEGF receptors 1 and 2 in focal cortical dysplasia type IIB. Acta Neuropathol 2008, 115(6):683-696.
17. Boer K., Troost D., Timmermans W., van Rijen P.C., Spliet W.G., Aronica E. Pi3K-mTOR signaling and AMOG expression in epilepsy-associated glioneuronal tumors. Brain Pathol 2010, 20(1):234-244.
18. Bosnjak V.M., Dakovic I., Duranovic V., Lujic L., Krakar G., Marn B. Malformations of cortical development in children with congenital cytomegalovirus infection - a study of nine children with proven congenital cytomegalovirus infection. Coll Antropol 2011, 35(Suppl. 1):229-234.
19. Bourneville D. Sclérose tubéreuse des circonvolutions cérébrales: idiotie et épilepsie hémiplégique. Arch Neurol (Paris) 1880, 1:81-91.
20. Buckmaster P.S., Lew F.H. Rapamycin suppresses mossy fiber sprouting but not seizure frequency in a mouse model of temporal lobe epilepsy. J Neurosci 2011, 31(6):2337-2347.
21. Butler M.G., Dasouki M.J., Zhou X.P., Talebizadeh Z., Brown M., Takahashi T.N., Miles J.H., Wang C.H., Stratton R., Pilarski R., Eng C. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 2005, 42:318-321.
22. Capo-Chichi J.M., Tcherkezian J., Hamdan F.F., Décarie J.C., Dobrzeniecka S., Patry L., Nadon M.A., Mucha B.E., Major P., Shevell M., Ouled Amar Bencheikh B., Joober R., Samuels M.E., Rouleau G.A., Roux P.P., Michaud J.L. Disruption of TBC1D7, a subunit of the TSC1-TSC2 protein complex, in intellectual disability and megalencephaly. J Med Genet 2013, [Epub ahead of print].
23. Chen B., Tardell C., Higgins B., Packman K., Boylan J.F., Niu H. BRAFV600E negatively regulates the AKT pathway in melanoma cell lines. PLoS One 2012, 7(8):e42598.
24. Chen J., Tsai V., Parker W.E., Aronica E., Baybis M., Crino P.B. Detection of human papillomavirus in human focal cortical dysplasia type IIB. Ann Neurol 2012, 72:881-892.
25. Cho C.H. Frontier of epilepsy research - mTOR signaling pathway. Exp Mol Med 2011, 43:231-274.
26. Chu-Shore C.J., Major P., Camposano S., Muzykewicz D., Thiele E.A. The natural history of epilepsy in tuberous sclerosis complex. Epilepsia 2010, 51:1236-1241.
27. Colombo N., Salamon N., Raybaud C., Ozkara C., Barkovich A.J. Imaging of malformations of cortical development. Epileptic Disord 2009, 11:194-205.
28. Cravioto H., Feigin I. Localized cerebral gliosis with giant neurons histologically resembling tuberous sclerosis. J Neuropathol Exp Neurol 1960, 19:572-579.
29. Crino P.B. Molecular pathogenesis of focal cortical dysplasia and hemimegalencephaly. J Child Neurol 2005, 20:330-336.
30. Crino P.B. Focal brain malformations: a spectrum of disorders along the mTOR cascade. Novartis Found Symp 2007, 288:260-272. discussion 272-281.
31. Crino P.B. mTOR: a pathogenic signaling pathway in developmental brain malformations. Trends Mol Med 2011, 17:734-742.
32. Crino P.B. Evolving neurobiology of tuberous sclerosis complex. Acta Neuropathol 2013, 125:317-332.
33. Crino P.B., Aronica E., Baltuch G., Nathanson K.L. Biallelic TSC gene inactivation in tuberous sclerosis complex. Neurology 2010, 74(21):1716-1723.
34. Crino P.B., Nathanson K.L., Henske E.P. The tuberous sclerosis complex. N Engl J Med 2006, 355:1345-1356.
35. Crome L. The morbid anatomy of epilepsy in mental deficiency. Proc R Soc Med 1954, 47:850-852.
36. Dibble C.C., Elis W., Menon S., Qin W., Klekota J., Asara J.M., Finan P.M., Kwiatkowski D.J., Murphy L.O., Manning B.D. TBC1D7 is a third subunit of the TSC1-TSC2 complex upstream of mTORC1. Mol Cell 2012, 47:535-546.
37. Dobashi Y., Watanabe Y., Miwa C., Suzuki S., Koyama S. Mammalian target of rapamycin: a central node of complex signaling cascades. Int J Clin Exp Pathol 2011, 4(5):476-495.
38. Ertan G., Arulrajah S., Tekes A., Jordan L., Huisman T.A. Cerebellar abnormality in children and young adults with tuberous sclerosis complex: MR and diffusion weighted imaging findings. J Neuroradiol 2010, 37(4):231-238.
39. Falconer M.A., Pond D.A., Meyer A., Woolf A.L. Temporal lobe epilepsy with personality and behaviour disorders caused by an unusual calcifying lesion; report of two cases in children relieved by temporal lobectomy. J Neurol Neurosurg Psychiatry 1953, 16:234-244.
40. Faustino A., Couto J.P., Pópulo H., Rocha A.S., Pardal F., Cameselle-Teijeiro J.M., Lopes J.M., Sobrinho-Simões M., Soares P. MTOR pathway overactivation in BRAF mutated papillary thyroid carcinoma. J Clin Endocrinol Metab 2012, 97(7):E1139-E1149.
41. Feliciano D.M., Su T., Lopez J., Platel J.C., Bordey A. Single-cell Tsc1 knockout during corticogenesis generates tuber-like lesions and reduces seizure threshold in mice. J Clin Invest 2011, 121:1596-1607.
42. Flores-Sarnat L., Sarnat H.B., Davila-Gutierrez G., Alvarez A. Hemimegalencephaly: part 2. Neuropathology suggests a disorder of cellular lineage. J Child Neurol 2003, 18:776-785.
43. Fule T., Mathe M., Suba Z., Csapo Z., Szarvas T., Tatrai P., Paku S., Kovalszky I. The presence of human papillomavirus 16 in neural structures and vascular endothelial cells. Virology 2006, 348:289-296.
44. Galanopoulou A.S., Gorter J.A., Cepeda C. Finding a better drug for epilepsy: the mTOR pathway as an antiepileptogenic target. Epilepsia 2012, 53(7):1119-1130.
45. Goto J., Talos D.M., Klein P., Qin W., Chekaluk Y.I., Anderl S., Malinowska I.A., Di Nardo A., Bronson R.T., Chan J.A., Vinters H.V., Kernie S.G., Jensen F.E., Sahin M., Kwiatkowski D.J. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex. Proc Natl Acad Sci USA 2011, 108:E1070-E1079.
46. Gumbinger C., Rohsbach C.B., Schulze-Bonhage A., Korinthenberg R., Zentner J., Haffner M., Fauser S. Focal cortical dysplasia: a genotype-phenotype analysis of polymorphisms and mutations in the TSC genes. Epilepsia 2009, 50:1396-1408.
47. Hsu P.P., Kang S.A., Rameseder J., Zhang Y., Ottina K.A., Lim D., Peterson T.R., Choi Y., Gray N.S., Yaffe M.B., Marto J.A., Sabatini D.M. The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. Science 2011, 332:1317-1322.
48. Jacinto E., Loewith R., Schmidt A., Lin S., Ruegg M.A., Hall A., Hall M.N. Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol 2004, 6:1122-1128.
49. Koelsche C., Wohrer A., Jeibmann A., Schittenhelm J., Schindler G., Preusser M., Lasitschka F., von Deimling A., Capper D. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol 2013.
50. Krsek P., Maton B., Korman B., Pacheco-Jacome E., Jayakar P., Dunoyer C., Rey G., Morrison G., Ragheb J., Vinters H.V., Resnick T., Duchowny M. Different features of histopathological subtypes of pediatric focal cortical dysplasia. Ann Neurol 2008, 63:758-769.
51. Krueger D.A., Care M.M., Holland K., Agricola K., Tudor C., Mangeshkar P., Wilson K.A., Byars A., Sahmoud T., Franz D.N. Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis. N Engl J Med 2010, 363:1801-1811.
52. Kwiatkowski D.J., Zhang H., Bandura J.L., Heiberger K.M., Glogauer M., el-Hashemite N., Onda H. A mouse model of TSC1 reveals sex-dependent lethality from liver hemangiomas, and up-regulation of p70S6 kinase activity in Tsc1 null cells. Hum Mol Genet 2002, 11:525-534.
53. Kwon C.H., Luikart B.W., Powell C.M., Zhou J., Matheny S.A., Zhang W., Li Y., Baker S.J., Parada L.F. Pten regulates neuronal arborization and social interaction in mice. Neuron 2006, 50:377-388.
54. Kwon C.H., Zhu X., Zhang J., Baker S.J. MTor is required for hypertrophy of Pten-deficient neuronal soma in vivo. Proc Natl Acad Sci USA 2003, 100:12923-12928.
55. Lee J.H., Huynh M., Silhavy J.L., Kim S., Dixon-Salazar T., Heiberg A., Scott E., Bafna V., Hill K.J., Collazo A., Funari V., Russ C., Gabriel S.B., Mathern G.W., Gleeson J.G. De novo somatic mutations in components of the PI3K-AKT3-mTOR pathway cause hemimegalencephaly. Nat Genet 2012, 44:941-945.
56. Lee A., Maldonado M., Baybis M., Walsh C.A., Scheithauer B., Yeung R., Parent J., Weiner H.L., Crino P.B. Markers of cellular proliferation are expressed in cortical tubers. Ann Neurol 2003, 53(5):668-673.
57. Ljungberg M.C., Bhattacharjee M.B., Lu Y., Armstrong D.L., Yoshor D., Swann J.W., Sheldon M., D'Arcangelo G. Activation of mammalian target of rapamycin in cytomegalic neurons of human cortical dysplasia. Ann Neurol 2006, 60:420-429.
58. Loewith R., Jacinto E., Wullschleger S., Lorberg A., Crespo J.L., Bonenfant D., Oppliger W., Jenoe P., Hall M.N. Two TOR complexes, only one of which is rapamycin sensitive, have distinct roles in cell growth control. Mol Cell 2002, 10:457-468.
59. Lu Z., Hu X., Li Y., Zheng L., Zhou Y., Jiang H., Ning T., Basang Z., Zhang C., Ke Y. Human papillomavirus 16 E6 oncoprotein interferences with insulin signaling pathway by binding to tuberin. J Biol Chem 2004, 279:35664-35670.
60. Ma J., Meng Y., Kwiatkowski D.J., Chen X., Peng H., Sun Q., Zha X., Wang F., Wang Y., Jing Y., Zhang S., Chen R., Wang L., Wu E., Cai G., Malinowska-Kolodziej I., Liao Q., Liu Y., Zhao Y., Sun Q., Xu K., Dai J., Han J., Wu L., Zhao R.C., Shen H., Zhang H. Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. J Clin Invest 2010, 120:103-114.
61. Manoranjan B., Provias J.P. Hemimegalencephaly: a fetal case with neuropathological confirmation and review of the literature. Acta Neuropathol 2010, 120:117-130.
62. Marcotte L., Aronica E., Baybis M., Crino P.B. Cytoarchitectural alterations are widespread in cerebral cortex in tuberous sclerosis complex. Acta Neuropathol 2012, 123(5):685-693.
63. Marucci G., Martinoni M., Giulioni M. Relationship between focal cortical dysplasia and epilepsy-associated low-grade tumors: an immunohistochemical study. APMIS: acta pathologica, microbiologica, et immunologica. Scandinavica 2013, 121:22-29.
64. Meikle L., Talos D.M., Onda H., Pollizzi K., Rotenberg A., Sahin M., Jensen F.E., Kwiatkowski D.J. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival. J Neurosci 2007, 27:5546-5558.
65. Menon S., Manning B.D. Common corruption of the mTOR signaling network in human tumors. Oncogene 2008, 27(Suppl. 2):S43-S51.
66. Mischel P.S., Nguyen L.P., Vinters H.V. Cerebral cortical dysplasia associated with pediatric epilepsy. Review of neuropathologic features and proposal for a grading system. J Neuropathol Exp Neurol 1995, 54:137-153.
67. Miyata H., Chiang A.C., Vinters H.V. Insulin signaling pathways in cortical dysplasia and TSC-tubers: tissue microarray analysis. Ann Neurol 2004, 56:510-519.
68. Muhlebner A., Coras R., Kobow K., Feucht M., Czech T., Stefan H., Weigel D., Buchfelder M., Holthausen H., Pieper T., Kudernatsch M., Blumcke I. Neuropathologic measurements in focal cortical dysplasias: validation of the ILAE 2011 classification system and diagnostic implications for MRI. Acta Neuropathol 2012, 123:259-272.
69. Orlova K.A., Crino P.B. The tuberous sclerosis complex. Ann N Y Acad Sci 2010, 1184:87-105.
70. Orlova K.A., Parker W.E., Heuer G.G., Tsai V., Yoon J., Baybis M., Fenning R.S., Strauss K., Crino P.B. STRADalpha deficiency results in aberrant mTORC1 signaling during corticogenesis in humans and mice. J Clin Invest 2010, 120:1591-1602.
71. Orlova K.A., Tsai V., Baybis M., Heuer G.G., Sisodiya S., Thom M., Strauss K., Aronica E., Storm P.B., Crino P.B. Early progenitor cell marker expression distinguishes type II from type I focal cortical dysplasias. J Neuropathol Exp Neurol 2010, 69:850-863.
72. Palmini A., Najm I., Avanzini G., Babb T., Guerrini R., Foldvary-Schaefer N., Jackson G., Luders H.O., Prayson R., Spreafico R., Vinters H.V. Terminology and classification of the cortical dysplasias. Neurology 2004, 62:S2-S8.
73. Parker W.E., Orlova K.A., Heuer G.G., Baybis M., Aronica E., Frost M., Wong M., Crino P.B. Enhanced epidermal growth factor, hepatocyte growth factor, and vascular endothelial growth factor expression in tuberous sclerosis complex. Am J Pathol 2011, 178(1):296-305.
74. Parker W.E., Orlova K.A., Parker W.H., Birnbaum J.F., Krymskaya V.P., Goncharov D.A., Baybis M., Helfferich J., Okochi K., Strauss K.A., Crino P.B. Rapamycin prevents seizures after depletion of STRADA in a rare neurodevelopmental disorder. Sci Transl Med 2013, 5(182):182ra53.
75. Poduri A., Evrony G.D., Cai X., Elhosary P.C., Beroukhim R., Lehtinen M.K., Hills L.B., Heinzen E.L., Hill A., Hill R.S., Barry B.J., Bourgeois B.F., Riviello J.J., Barkovich A.J., Black P.M., Ligon K.L., Walsh C.A. Somatic activation of AKT3 causes hemispheric developmental brain malformations. Neuron 2012, 74:41-48.
76. Prabowo A.S., Anink J.J., Lammens M., Nellist M., van den Ouweland A.M., Adle-Biassette H., Sarnat H.B., Flores-Sarnat L., Crino P.B., Aronica E. Fetal brain lesions in tuberous sclerosis complex: TORC1 activation and inflammation. Brain Pathol 2013, 23(1):45-59. [Epub 2012 Aug 30]. 10.1111/j.1750-3639.2012.00616.x.
77. Puffenberger E.G., Strauss K.A., Ramsey K.E., Craig D.W., Stephan D.A., Robinson D.L., Hendrickson C.L., Gottlieb S., Ramsay D.A., Siu V.M., Heuer G.G., Crino P.B., Morton D.H. Polyhydramnios, megalencephaly and symptomatic epilepsy caused by a homozygous 7-kilobase deletion in LYK5. Brain 2007, 130:1929-1941.
78. Qin W., Chan J.A., Vinters H.V., Mathern G.W., Franz D.N., Taillon B.E., Bouffard P., Kwiatkowski D.J. Analysis of TSC cortical tubers by deep sequencing of TSC1, TSC2 and KRAS demonstrates that small second-hit mutations in these genes are rare events. Brain Pathol 2010, 20(6):1096-1105.
79. Raffo E., Coppola A., Ono T., Briggs S.W., Galanopoulou A.S. A pulse rapamycin therapy for infantile spasms and associated cognitive decline. Neurobiol Dis 2011, 201143(2):322-329.
80. Reith R.M., McKenna J., Wu H., Hashmi S.S., Cho S.H., Dash P.K., Gambello M.J. Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex. Neurobiol Dis 2013, 51:93-103.
81. Reith R.M., Way S., McKenna J., Haines K., Gambello M.J. Loss of the tuberous sclerosis complex protein tuberin causes Purkinje cell degeneration. Neurobiol Dis 2011, 43(1):113-122.
82. Riviere J.B., Mirzaa G.M., O'Roak B.J., Beddaoui M., Alcantara D., Conway R.L., St-Onge J., Schwartzentruber J.A., Gripp K.W., Nikkel S.M., Worthylake T., Sullivan C.T., Ward T.R., Butler H.E., Kramer N.A., Albrecht B., Armour C.M., Armstrong L., Caluseriu O., Cytrynbaum C., Drolet B.A., Innes A.M., Lauzon J.L., Lin A.E., Mancini G.M., Meschino W.S., Reggin J.D., Saggar A.K., Lerman-Sagie T., Uyanik G., Weksberg R., Zirn B., Beaulieu C.L., Majewski J., Bulman D.E., O'Driscoll M., Shendure J., Graham J.M., Boycott K.M., Dobyns W.B. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 2012, 44:934-940.
83. Rombaldi R.L., Serafini E.P., Mandelli J., Zimmermann E., Losquiavo K.P. Transplacental transmission of human papillomavirus. Virol J 2008, 5:106.
84. Russell R.C., Fang C., Guan K.L. An emerging role for TOR signaling in mammalian tissue and stem cell physiology. Development 2011, 138:3343-3356.
85. Sabers C.J., Martin M.M., Brunn G.J., Williams J.M., Dumont F.J., Wiederrecht G., Abraham R.T. Isolation of a protein target of the FKBP12-rapamycin complex in mammalian cells. J Biol Chem 1995, 270:815-822.
86. Samadani U., Judkins A.R., Akpalu A., Aronica E., Crino P.B. Differential cellular gene expression in ganglioglioma. Epilepsia 2007, 48:646-653.
87. Schick V., Majores M., Engels G., Hartmann W., Elger C.E., Schramm J., Schoch S., Becker A.J. Differential Pi3K-pathway activation in cortical tubers and focal cortical dysplasias with balloon cells. Brain Pathol 2007, 17:165-173.
88. Schick V., Majores M., Koch A., Elger C.E., Schramm J., Urbach H., Becker A.J. Alterations of phosphatidylinositol 3-kinase pathway components in epilepsy-associated glioneuronal lesions. Epilepsia 2007, 48(Suppl. 5):65-73.
89. Schindler G., Capper D., Meyer J., Janzarik W., Omran H., Herold-Mende C., Schmieder K., Wesseling P., Mawrin C., Hasselblatt M., Louis D.N., Korshunov A., Pfister S., Hartmann C., Paulus W., Reifenberger G., von Deimling A. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011, 121:397-405.
90. Sha L.Z., Xing X.L., Zhang D., Yao Y., Dou W.C., Jin L.R., Wu L.W., Xu Q. Mapping the spatio-temporal pattern of the mammalian target of rapamycin (mTOR) activation in temporal lobe epilepsy. PLoS One 2012, 7(6):e39152.
91. Sims J. On hypertrophy and atrophy of the brain. Med Chir Trans 1835, 19:315-380.
92. Sisodiya S.M. Malformations of cortical development: burdens and insights from important causes of human epilepsy. Lancet Neurol 2004, 3:29-38.
93. Sliwa A., Plucinska G., Bednarczyk J., Lukasiuk K. Post-treatment with rapamycin does not prevent epileptogenesis in the amygdala stimulation model of temporal lobe epilepsy. Neurosci Lett 2012, 509(2):105-109.
94. Sosunov A.A., Wu X., McGovern R.A., Coughlin D.G., Mikell C.B., Goodman R.R., McKhann G.M. The mTOR pathway is activated in glial cells in mesial temporal sclerosis. Epilepsia 2012, 53(Suppl. 1):78-86.
95. Southwell D.G., Garcia P.A., Berger M.S., Barbaro N.M., Chang E.F. Long-term seizure control outcomes after resection of gangliogliomas. Neurosurgery 2012, 70:1406-1413. discussion 1413-1404.
96. Spangle J.M., Munger K. The human papillomavirus type 16 E6 oncoprotein activates mTORC1 signaling and increases protein synthesis. J Virol 2010, 84:9398-9407.
97. Talos D.M., Kwiatkowski D.J., Cordero K., Black P.M., Jensen F.E. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers. Ann Neurol 2008, 63(4):454-465.
98. Talos D.M., Sun H., Zhou X., Fitzgerald E.C., Jackson M.C., Klein P.M., Lan V.J., Joseph A., Jensen F.E. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. PLoS One 2012, 7:e35885.
99. Tassi L., Colombo N., Garbelli R., Francione S., Lo Russo G., Mai R., Cardinale F., Cossu M., Ferrario A., Galli C., Bramerio M., Citterio A., Spreafico R. Focal cortical dysplasia: neuropathological subtypes, EEG, neuroimaging and surgical outcome. Brain 2002, 125:1719-1732.
100. Taylor D.C., Falconer M.A., Bruton C.J., Corsellis J.A. Focal dysplasia of the cerebral cortex in epilepsy. J Neurol Neurosurg Psychiatry 1971, 34:369-387.
101. Tsai P.T., Greene-Colozzi E., Goto J., Anderl S., Kwiatkowski D.J., Sahin M. Prenatal rapamycin results in early and late behavioral abnormalities in wildtype C57Bl/6 mice. Behav Genet 2013, 43(1):51-59.
102. Tsai P.T., Hull C., Chu Y., Greene-Colozzi E., Sadowski A.R., Leech J.M., Steinberg J., Crawley J.N., Regehr W.G., Sahin M. Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 2012, 488(7413):647-651.
103. Tsai V., Parker W.E., Orlova K.A., Baybis M., Chi A.W., Berg B.D., Birnbaum J.F., Estevez J., Okochi K., Sarnat H.B., Flores-Sarnat L., Aronica E., Crino P.B. Fetal brain mTOR signaling activation in tuberous sclerosis complex. Cereb Cortex 2012, [Epub ahead of print].
104. Urbanska M., Gozdz A., Swiech L.J., Jaworski J. Mammalian target of rapamycin complex 1 (mTORC1) and 2 (mTORC2) control the dendritic arbor morphology of hippocampal neurons. J Biol Chem 2012, 287:30240-30256.
105. van Vliet E.A., Forte G., Holtman L., den Burger J.C., Sinjewel A., de Vries H.E., Aronica E., Gorter J.A. Inhibition of mammalian target of rapamycin reduces epileptogenesis and blood-brain barrier leakage but not microglia activation. Epilepsia 2012, 53(7):1254-1263.
106. Vaughn J., Hagiwara M., Katz J., Roth J., Devinsky O., Weiner H. Milla S (2013) MRI characterization and longitudinal study of focal cerebellar lesions in a young tuberous sclerosis cohort. AJNR Am J Neuroradiol 2013, 34(3):655-659.
107. Way S.W., McKenna J., Mietzsch U., et al. Loss of Tsc2 in radial glia models the brain pathology of tuberous sclerosis complex in the mouse. Hum Mol Genet 2009, 18:1252-1265.
108. Way S.W., Rozas N.S., Wu H.C., McKenna J., Reith R.M., Hashmi S.S., Dash P.K., Gambello M.J. The differential effects of prenatal and/or postnatal rapamycin on neurodevelopmental defects and cognition in a neuroglial mouse model of tuberous sclerosis complex. Hum Mol Genet 2012, 21(14):3226-3236.
109. Weber J.D., Gutmann D.H. Deconvoluting mTOR biology. Cell Cycle 2012, 11:236-248.
110. Wong M. Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation. Epilepsia 2008, 49:8-21.
111. Wong M., Crino P.B. MTOR and epileptogenesis in developmental brain malformations. Jasper's basic mechanisms of the epilepsies 2012, Oxford University Press, Bethesda, MD. J.L. Noebels (Ed.).
112. Zeng L.H., Rensing N.R., Wong M. The mammalian target of rapamycin signaling pathway mediates epileptogenesis in a model of temporal lobe epilepsy. J Neurosci 2009, 29:6964-6972.
113. Zeng L.H., Rensing N.R., Zhang B., Gutmann D.H., Gambello M.J., Wong M. Tsc2 gene inactivation causes a more severe epilepsy phenotype than Tsc1 inactivation in a mouse model of tuberous sclerosis complex. Hum Mol Genet 2011, 20:445-454.
114. Zeng L.H., Xu L., Gutmann D.H., Wong M. Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex. Ann Neurol 2008, 63:444-453.
115. Zoncu R., Efeyan A., Sabatini D.M. MTOR: from growth signal integration to cancer, diabetes and ageing. Nat Rev Mol Cell Biol 2011, 12:21-35.